StemCell Therapy

The 38 rating InvestorsObserver gives to Aikido Pharma Inc (AIKI) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 33 percent of stocks in the Biotechnology industry, AIKIs 38 overall rating means the stock scores better than 38 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 38 would rank higher than 38 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Aikido Pharma Inc (AIKI) stock is lower by -9.23% while the S&P 500 has gained 1.79% as of 3:19 PM on Monday, Feb 1. AIKI is down -$0.15 from the previous closing price of $1.68 on volume of 7,900,423 shares. Over the past year the S&P 500 has risen 16.37% while AIKI has gained 51.49%. AIKI lost -$0.75 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Aikido Pharma Inc (AIKI) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

See more here:
Where Does Aikido Pharma Inc (AIKI) Stock Fall in the Biotechnology Field? - InvestorsObserver

This entry was posted on February 3, 2021 at 8:50 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |